| 段晓伟 孔德润 刘卫 李远美 刘嵬 唐郡.复合乳酸杆菌治疗肝硬化失代偿期患者效果分析[J].现代生物医学进展英文版,2015,15(25):4919-4922. |
| 复合乳酸杆菌治疗肝硬化失代偿期患者效果分析 |
| Effect of Composite Lactobacllus in Patients with Decompensated Cirrhosis |
| |
| DOI： |
| 中文关键词: 肝硬化失代偿期 复合乳酸杆菌 肝功能 |
| 英文关键词: Decompensated cirrhosis Composite lactobacillus Liver function |
| 基金项目:国家自然科学基金项目( 81271736) |
|
| Hits: 595 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨分析复合乳酸杆菌在治疗肝硬化失代偿期患者中的效果。方法：选择2011 年1 月~2014 年12 月间在我院住院治
疗的54 例肝硬化失代偿期患者为研究对象，随机分为观察组和对照组各27 例，选取同时期健康体检者27例为健康对照组。观
察组患者接受复合乳酸杆菌联合肝硬化常规治疗，对照组仅接受肝硬化常规治疗。治疗8周后，比较对照组和观察组治疗前后及
健康对照组患者血浆ALT、AST、内毒素、IL-1beta、TNF-alpha、血氨及消化道症状积分的差异。结果：观察组和对照组患者治疗前血浆
ALT、AST、内毒素、IL-1beta、TNF-alpha、血氨水平及消化道症状积分差异无统计学意义(P＞0.05)，均明显高于健康对照组（P < 0.05）；治
疗后两组患者上述指标均明显降低(P<0.05)，但观察组较对照组下降更为明显(P < 0.05)。结论：复合乳酸杆菌联合常规疗法在肝
硬化失代偿期患者的治疗方面发挥了重要作用，值得临床推广。 |
| 英文摘要: |
| Objective:To investigate the efficacy of composite lactobacillus in patients with decompensated cirrhosis.Methods:54
patients with decompensated cirrhosis in our hospital from January 2011 to December 2014 were chosen as research objects who were
divided into two groups randomly, named as observation group (27 cases) and control group (27 cases). Patients in observation group
were received routine treatment combined with composite Lactobacillus, while patients in control group were only received routine
treatment for cirrhosis . At the same period, 27 healthy cases were selected as healthy control group. After 8 weeks of treatment, the
differences of the serum ALT, AST, endotoxin, IL-1beta, TNF-alpha, blood ammonia and gastrointestinal symptom score before and after
treatment in observation group and control group and in healthy control group were compared.Results:Before treatment, the serum ALT,
AST, endotoxin, IL-1beta, TNF-alpha, blood ammonia and gastrointestinal symptom score between observation group and control group had no
statistically difference (P＞0.05), but higher than healthy control group (P <0.05); After treatment, these indicators in both observation
group and control group were lower than before (P<0.05), and the observation group was decreased more significantly than the control
group (P<0.05).Conclusion:Composite lactobacillus combined with routine treatment plays an important role in the treatment of patients
with decompensated cirrhosis, is worthy of clinical promotion. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
